Inventor · disambiguated record
Michael Molhoj
Also filed as: MOLHOJ MICHAEL
24 granted patents·26 pending applications·86 citations·filing 2015–2025
95Inventor score
Top patents by PatentIndex Score
50 records- 0195US11286300B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 29, 2022·11 cites·8 claims
- 0295US10941205B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 9, 2021·10 cites·13 claims
- 0394US9914776B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2015·Granted Mar 13, 2018·16 cites·42 claims
- 0492US11117965B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Granted Sep 14, 2021·2 cites·35 claims
- 0592US10611841B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·41 claims
- 0692US10611840B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·5 claims
- 0791US11603411B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 14, 2023·9 cites·5 claims
- 0891US10822402B2Humanized anti-tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2017·Granted Nov 3, 2020·4 cites·12 claims
- 0990US12030952B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Jul 9, 2024·1 cites·10 claims
- 1090US11958912B2Method for determining the in vivo interaction modeHOFFMANN LA ROCHE·Filed 2020·Granted Apr 16, 2024·2 cites·34 claims
- 1188US11787868B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·1 cites·5 claims
- 1287US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 1387US2024141044A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1485US9862763B2Humanized anti-tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Jan 9, 2018·4 cites·13 claims
- 1585US2025297025A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 1684US12297263B2Humanized anti-Tau(PS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted May 13, 2025·0 cites·6 claims
- 1784US2023287118A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1883US10730938B2Bispecific antibodies and methods of use in ophthalmologyHOFFMANN LA ROCHE·Filed 2017·Granted Aug 4, 2020·3 cites·13 claims
- 1983US2023365702A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2082US2022403027A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2182US2025376523A1Humanized anti-human cd19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2282US2024317879A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2381US12358997B1Bispecific anti-human A-beta/anti-human transferrin receptor antibodiesHOFFMANN LA ROCHE·Filed 2025·Granted Jul 15, 2025·0 cites·2 claims
- 2477US10538585B2Anti-ANG2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2017·Granted Jan 21, 2020·2 cites·6 claims
- 2576US12215152B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Feb 4, 2025·0 cites·8 claims
- 2676US11486882B2Method for detecting multispecific antibody light chain mispairingHOFFMANN LA ROCHE·Filed 2019·Granted Nov 1, 2022·2 cites·17 claims
- 2775US10766967B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Sep 8, 2020·1 cites·50 claims
- 2872US11572404B2Humanized anti-Tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Feb 7, 2023·0 cites·6 claims
- 2968US2022049020A1Tetravalent multispecific antibodiesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3067US12287335B2Direct affinity measurement of human IgG1 binding multimeric antigensHOFFMANN LA ROCHE·Filed 2020·Granted Apr 29, 2025·0 cites·22 claims
- 3167US11732036B2Antibody that binds to VEGF-A and ANG2 and methods of useHOFFMANN LA ROCHE·Filed 2021·Granted Aug 22, 2023·0 cites·9 claims
- 3267US2022363771A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3365US2020216554A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3462US2021309730A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3560US2020347147A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3659US2021070882A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3756US2017145116A1Tetravalent multispecific antibodiesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3852US2019016827A1Method for determining the in vivo interaction modeHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3951US2019018009A1Direct affinity measurement of human igg1 binding multimeric antigensHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 4046US11952421B2Bispecific antibodies against CD3EPSILON and ROR1BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 9, 2024·0 cites·6 claims
- 4146US2017129962A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4246US2021206806A1Peptidic linker with reduced post-translational modificationHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4346US2017115304A1Method for detecting multispecific antibody light chain mispairingHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4445US2017174786A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4543US2017114146A1Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4641US2015315296A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 4740US2017096485A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4838US2017096495A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4938US2018282410A1Anti-cd3xrob04 bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 5033US2017306044A1Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancerENGMAB AG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Molhoj files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →